不整脈　2019

出版社： メディカルレビュー社
著者：
発行日： 2019-09-18
分野： 臨床医学：内科  >  心臓
ISBN： 9784779222702
電子書籍版： 2019-08-21 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

不整脈治療の最新トピックスを、臨床と関わりの深い基礎的研究も含めて、詳細かつわかりやすく解説する。２０１９は、「構造からみた不整脈と心臓神経」「自律神経と不整脈」など、２０のトピックスを収録。

目次

  • 基礎
    １．心房細動の発生機序―炎症性心房線維化の視点から―
    ２．心臓伝達障害の分子病態と遺伝子異常
    ３．遺伝子病としての不整脈：遺伝子診断の光と影
    ４．iPS細胞を用いた不整脈研究
    ５．構造からみた不整脈と心臓神経

    臨床
    １．反射性失神による心停止とベーシング治療
    ２．自律神経と不整脈
    ３．心房細動検出のデバイス
    ４．心房細動登録研究から学ぶ：わかったことと課題
    ５．心房細動と抗凝固療法：現状、課題、展望
    ６．心房細動アブレーション：現状と課題
    ７．心房細動アブレーションの合併症
    ８．化学的アブレーション：現状と将来展望
    ９．心室性不整脈のアブレーション：現状と課題
    10．Purkinjeの繊維由来心室不整脈
    11．遺伝子病としての致死性不整脈：現状と課題
    12．不整脈デバイス治療：現状と課題
    13．小児の重症不整脈
    14．院外救命における市民AEDの活躍とさらなる可能性
    15．服薬アドヒアランスについて：抗凝固薬を中心に

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

基礎

P.29 掲載の参考文献
1) Chung MK, et al. C-reactive protein elevation in patients with atrial arrhythmias : inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001 ; 104 : 2886-91.
PubMed
2) Conway DS, et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004 ; 43 : 2075-82.
 
3) Sata N, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J. 2004 ; 45 : 441-5.
PubMed
4) Yamashita T, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J. 2010 ; 74 : 262-70.
PubMed
5) Sonoda Y, et al. Macrophage infiltration into the endothelium of atrial tissue in atrial fibrillation. Circ J. 2017 ; 25 ; 81 : 1742-4.
 
6) Kume O, et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm. 2011 ; 8 : 278-85.
PubMed
7) Kume O, et al. Role of atrial endothelial cells in the development of atrial fibrosis and fibrillation in response to pressure overload. Cardiovasc Pathol. 2017 ; 27 : 18-25.
PubMed
8) Pathak RK, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort : a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015 ; 65 : 2159-69.
 
9) Fukui A, et al. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol. 2013 ; 6 : 402-9.
PubMed
10) Fukui A, et al. Hyperleptinemia exacerbates high-fat diet-mediated atrial fibrosis and fibrillation. J Cardiovasc Electrophysiol. 2017 ; 28 : 702-10.
PubMed
11) Fukunaga N, et al. Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role of oxidative stress. Heart Rhythm. 2012 ; 9 : 2023-31.
 
12) Aoki K, et al. Role of indoxyl sulfate as a predisposing factor for atrial fibrillation in Renal dysfunction. J Am Heart Assoc. 2015 ; 9 ; 4 : e002023.
 
13) Yamagami F, et al. Indoxyl sulphate is associated with atrial fibrillation recurrence after catheter ablation. Sci Rep. 2018 ; 8 : 17276.
PubMed
14) Kondo H, et al. Splenectomy exacerbates atrial inflammatory fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats : Possible role of spleen-derived interleukin-10. Heart Rhythm. 2016 ; 13 : 241-50.
PubMed
15) Kondo H, et al. Interleukin 10 treatment ameliorates high-fat diet-induced inflammatory atrial remodeling and fibrillation. Circ Arrhythm Electrophysiol. 2018 ; 11 : e006040.
PubMed
16) Garcia MJ, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974 ; 23 : 105-11.
PubMed
17) Benjamin EJ, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994 ; 271 : 840-4.
 
18) Huxley RR, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011 ; 108 : 56-62.
PubMed
19) Kato T, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol. 2006 ; 17 : 890-4.
 
20) Saito S, et al. Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats. Cardiovasc Res. 2014 ; 104 : 5-14.
PubMed
21) Lip GY, et al. Diabetes mellitus and atrial fibrillation : perspectives on epidemiological and pathophysiological links. Int J Cardiol. 2005 ; 105 : 319-21.
PubMed
22) Al Chekakie MO, et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol. 2010 ; 56 : 784-8.
PubMed
23) Hirata Y, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol. 2011 ; 58 : 248-55.
PubMed
24) Tian Z, et al. Perivascular adipose tissue-secreted angiopoietin-like protein 2 (Angptl2) accelerates neointimal hyperplasia after endovascular injury. J Mol Cell Cardiol. 2013 ; 57 : 1-12.
PubMed
25) Abe I, et al. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm. 2018 ; 15 : 1717-27.
PubMed
26) Zghaib T, et al. Association of left atrial epicardial adipose tissue with electrogram bipolar voltage and fractionation : electrophysiologic substrates for atrial fibrillation. Heart Rhythm. 2016 ; 13 : 2333-9.
PubMed
27) Mahajan R, et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol. 2015 ; 66 : 1-11.
 
P.38 掲載の参考文献
1) Priori SG, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 ; 10 : 1932-63.
PubMed
2) Lakatta EG, et al. A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. Circ Res. 2010 ; 106 : 659-73.
 
3) Remme CA. Cardiac sodium channelopathy associated with SCN5A mutations : electrophysiological, molecular and genetic aspects. J Physiol. 2013 ; 591 : 4099-116.
PubMed
4) Makita N, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008 ; 118 : 2219-29.
PubMed
5) Abe K, et al. Sodium channelopathy underlying familial sick sinus syndrome with early onset and predominantly male characteristics. Circ Arrhythm Electrophysiol. 2014 ; 7 : 511-7.
PubMed
6) Takehara N, et al. A cardiac sodium channel mutation identified in Brugada syndrome associated with atrial standstill. J Intern Med. 2004 ; 255 : 137-42.
PubMed
7) Verkerk AO, et al. Pacemaker activity of the human sinoatrial node : effects of HCN4 mutations on the hyperpolarization-activated current. Europace. 2014 ; 16 : 384-95.
PubMed
8) Ishikawa T, et al. Sick sinus syndrome with HCN4 mutations shows early onset and frequent association with atrial fibrillation and left ventricular noncompaction. Heart Rhythm. 2017 ; 14 : 717-24.
PubMed
9) Holm H, et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet. 2011 ; 43 : 316-20.
 
10) Ishikawa T, et al. Novel mutation in the α-myosin heavy chain gene is associated with sick sinus syndrome. Circ Arrhythm Electrophysiol. 2015 ; 8 : 400-8.
 
11) Baig SM, et al. Loss of Ca (v) 1. 3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nat Neurosci. 2011 ; 14 : 77-84.
 
12) Mohler PJ, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci U S A. 2004 ; 101 : 9137-42.
PubMed
13) Postma AV, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2002 ; 91 : e21-6.
PubMed
14) Disertori M, et al. Autosomal recessive atrial dilated cardiomyopathy with standstill evolution associated with mutation of Natriuretic Peptide Precursor A. Circ Cardiovasc Genet. 2013 ; 6 : 27-36.
PubMed
15) Fatkin D, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999 ; 341 : 1715-24.
PubMed
16) Schott JJ, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet. 1999 ; 23 : 20-1.
PubMed
17) Makita N, et al. A connexin40 mutation associated with a malignant variant of progressive familial heart block type I. Circ Arrhythm Electrophysiol. 2012 ; 5 : 163-72.
PubMed
18) Zhang L, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations : characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation. 2005 ; 111 : 2720-6.
 
19) Kruse M, et al. Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I. J Clin Invest. 2009 ; 119 : 2737-44.
 
20) Clemen CS, et al. Desminopathies : pathology and mechanisms. Acta Neuropathol. 2013 ; 125 : 47-75.
PubMed
21) Basson CT, et al. Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet. 1997 ; 15 : 30-5.
PubMed
22) Schott JJ, et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science. 1998 ; 281 : 108-11.
PubMed
23) Seki A, et al. Progressive atrial conduction defects associated with bone malformation caused by a connexin-45 mutation. J Am Coll Cardiol. 2017 ; 70 : 358-70.
PubMed
P.46 掲載の参考文献
1) Horie M. Molecular genetics have opened a new era for arrhythmia research, but also Pandoras box? J Arrhythm. 2016 ; 32 : 313-4.
 
2) Richards S, et al ; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 ; 17 : 405-24.
PubMed
3) Collins FS, et al. The Human Genome Project : lessons from large-scale biology. Science. 2003 ; 300 : 286-90.
PubMed
4) Curran ME, et al. A molecular basis for cardiac arrhythmia : HERG mutations cause long QT syndrome. Cell. 1995 ; 80 : 795-803.
PubMed
5) Wang Q, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995 ; 80 : 805-11.
PubMed
6) Sanguinetti MC, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia : HERG encodes the IKr potassium channel. Cell. 1995 ; 81 : 299-307.
 
7) Horie M, et al. Disorders of cardiac repolarization : long QT and short QT syndromes. Circ J. 2007 ; 71 (Suppl. A) : A50-3.
 
8) Priori SG, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 ; 10 : 1932-63.
PubMed
9) Nishio Y, et al. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol. 2009 ; 54 : 812-9.
PubMed
10) Vatta M, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet. 2002 ; 11 : 337-45.
PubMed
11) Maekawa K, et al. Genetic polymorphisms and haplotypes of the human cardiac sodium channel alpha subunit gene (SCN5A) in Japanese and their association with arrhythmia. Ann Hum Genet. 2005 ; 69 : 413-28.
PubMed
12) Cheng J, et al. Sudden unexplained nocturnal death syndrome in Southern China : an epidemiological survey and SCN5A gene screening. Am J Forensic Med Pathol. 2011 ; 32 : 359-63.
PubMed
13) Abe M, et al. Lack of modulatory effect of the SCN5A R1193Q polymorphism on cardiac fast Na+ current at body temperature. PLoS One. 2018 ; 13 : e0207437.
PubMed
14) Denham NC, et al. Systematic re-evaluation of SCN5A variants associated with Brugada syndrome. J Cardiovasc Electrophysiol. 2019 ; 30 : 118-27.
PubMed
15) ゲノム医療実現推進協議会平成29年度報告. 2018. https://www.kantei.go.jp/jp/singi/kenkouiryou/genome/pdf/h29_houkoku.pdf, (閲覧 : 2019-03-19)
 
16) NCBI. ClinVar. https://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/, (閲覧 : 2019-05-09)
 
P.55 掲載の参考文献
1) Takahashi K, et al. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 ; 126 : 663-76.
PubMed
2) Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 ; 131 : 861-72.
PubMed
3) Tanaka A, et al. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc. 2014 ; 3 : e001263.
PubMed
4) Kodaira M, et al. Impaired respiratory function in MELAS-induced pluripotent stem cells with high heteroplasmy levels. FEBS Open Bio. 2015 ; 5 : 219-25.
PubMed
5) Moretti A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010 ; 363 : 1397-409.
PubMed
6) Egashira T, et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res. 2012 ; 95 : 419-29.
PubMed
7) Kuroda Y, et al. Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes. Biochem Biophys Rep. 2017 ; 9 : 245-56.
PubMed
8) Seki T, et al. Derivation of induced pluripotent stem cells from human peripheral circulating T cells. Curr Protoc Stem Cell Biol. 2011 ; Chapter 4 : Unit4A. 3.
 
9) Seki T, et al. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc. 2012 ; 7 : 718-28.
PubMed
10) Seki T, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell stem cell. 2010 ; 7 : 11-4.
PubMed
11) Okata S, et al. Embryonic type Na+ channel β-subunit, SCN3B masks the disease phenotype of Brugada syndrome. Sci Rep. 2016 ; 6 : 34198.
 
12) Shimojima M, et al. Emerin plays a crucial role in nuclear invagination and in the nuclear calcium transient. Sci Rep. 2017 ; 7 : 44312.
 
P.68 掲載の参考文献
1) Armour JA, et al. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. Anat Rec. 1997 ; 247 : 289-98.
PubMed
2) Vaitkevicius R, et al. Nerve supply of the human pulmonary veins : an anatomical study. Heart Rhythm. 2009 ; 6 : 221-8.
PubMed
3) Bettoni M, et al. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. 2002 ; 105 : 2753-9.
PubMed
4) Amar D, et al. Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation. J Am Coll Cardiol. 2003 ; 42 : 1262-8.
PubMed
5) Arora R, et al. Neural substrate for atrial fibrillation : implications for targeted parasympathetic blockade in the posterior left atrium. Am J Physiol Heart Circ Physiol. 2008 ; 294 : H134-44.
PubMed
6) 井川修. 心臓構造からみた心房細動. 杉本恒明 (監), 井上博 (編), 不整脈 2017. 大阪 : メディカルレビュー社 ; 2017, p. 30-9.
 
7) 井川修, 他. 左房前壁に潜在する特殊な解剖学的構造. 心電図. 2008 ; 28 : 574-81.
Medical*Online
8) Igawa O. Focus on the atrial structure?Useful anatomical information for catheter ablation?. J Arrhythm. 2011 ; 27 : 268-88.
 
9) Igawa O, et al. Specific Myocardial Bundle of the Left Atrium, Right Lateral Ridge. The 83th Annual Scientific Meeting of the Japanese Circulation Society. 2019. 3. 31
 

臨床

P.75 掲載の参考文献
1) Brignole M, et al ; ESC Scientific Document Group. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018 ; 39 : 1883-948.
 
2) 日本循環器学会, 他. 失神の診断・治療ガイドライン (2012年改訂版). 2012. http://www.j-circ.or.jp/guideline/pdf/JCS2012_inoue_h.pdf, (閲覧 : 2019-03-12)
 
3) Kohno R, et al. Ambulatory electrocardiogram monitoring devices for evaluating transient loss of consciousness or other related symptoms. J Arrhythm. 2017 ; 33 : 583-9.
PubMed
4) Kohno R, et al. Syncope and ictal asystole caused by temporal lobe epilepsy. Circ J. 2011 ; 75 : 2508-10.
PubMed
5) Connolly SJ, et al. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol. 1999 ; 33 : 16-20.
PubMed
6) Sutton R, et al. Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope : pacemaker versus no therapy : a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators. Circulation. 2000 ; 102 : 294-9.
 
7) Ammirati F, et al ; Syncope Diagnosis and Treatment Study Investigators. Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope : a multicenter, randomized, controlled trial. Circulation. 2001 ; 104 : 52-7.
 
8) Connolly SJ, et al ; VPS II Investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope (VPS II) : a rabdomized trial. JAMA. 2003 ; 289 : 2224-9.
 
9) Brignole M, et al ; International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Pacemaker therapy in patients with neutrally mediated syncope and documented asystole : Third International Study on Syncope of Uncertain Etiology (ISSUE-3) : a randomized trial. Circulation. 2012 ; 125 : 2566-71.
 
10) Brignole M, et al ; International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Benefit of pacemaker therapy in patients woth presumed neutrally mediated syncope and documented asystole is greater when tilt test is negative : an analysis from the third International Study on Syncope of Uncertain Etiology (ISSUE-3). Circ Arrhythm Electrophysiol. 2014 ; 7 : 10-6.
 
11) Shen WK, et al. 2017 ACC/AHA/HRS Guideline for the evaluation and management of patients with syncope : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017 ; 136 : e25-59.
 
12) 日本循環器学会, 他. 不整脈非薬物治療ガイドライン (2018年改訂版). 2019. http://www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf, (閲覧 : 2019-04-05)
 
13) Kohno R, et al. Long-term follow-up of ictal asystole in temporal lobe epilepsy. Is permanent pacemaker therapy needed? J Cardiovasc Electrophysiol. 2016 ; 27 : 930-6.
PubMed
P.87 掲載の参考文献
1) Coumel P. Neural Aspects of paroxysmal atrial fibrillation. In : Falk RH, Podrid PJ, editors. Atrial Fibrillation : Mechanisms and Management. New York : Raven Press ; 1992. p. 109-25.
 
2) Lie JT, et al. Pathology of atrial fibrillation : Insights from autopsy studies. In : Falk RH, Podrid PJ, editors. Atrial Fibrillation : Mechanisms and Management. New York : Raven Press ; 1992. p. 1-14.
 
3) Pappano A. Parasympathetic control of cardiac electrical activity. In : Zipes DP, Jalife J, editors. Cardiac Electrophysiology : From Cell to Bedside. Philadelphia : Saunders ; 1990. p. 271-7.
 
4) Lindemann JP, et al. Sympathetic control of cardiac electrical activity. In : Zipes DP, Jalife J, editors. Cardiac Electrophysiology : From Cell to Bedside. Philadelphia : Saunders ; 1990. p. 277-83.
 
5) Chen LS, et al. Nerve sprouting and cardiac arrhythmias. In : Zipes DP, Jalife J, editors. Cardiac Electrophysiology : From Cell to Bedside (4th ed). Philadelphia : Saunders ; 2004. p. 299-305.
 
6) Han J, et al. Adrenergic effects on ventricular vulnerability. Circ Res. 1964 ; 14 : 516-24.
PubMed
7) Myerburg RJ, et al. Sudden cardiac death. In : Zipes DP, Jalife J, editors. Cardiac Electrophysiology : From Cell to Bedside (4th ed). Philadelphia : Saunders ; 2004. p. 720-31.
 
8) Tsukada T, et al. Circadian variation in out-of-hospital cardiac arrests due to cardiac cause in a Japanese patient population. Circ J. 2010 ; 74 : 1880-7.
 
9) Abe A, et al. Circadian variation of late potentials in idiopathic ventricular fibrillation associated with J waves : insights into alternative pathophysiology and risk stratification. Heart Rhythm. 2010 ; 7 : 675-82.
 
10) Abe A, et al. Comparison of late potentials for 24 hours between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy using a novel signal-averaging system based on Holter ECG. Circ Arrhythm Electrophysiol. 2012 ; 5 : 789-95.
PubMed
11) Akselrod S, et al. Power spectrum analysis of heart rate fluctuation : a quantitative probe of beat-to-beat cardiovascular control. Science. 1981 ; 213 : 220-2.
PubMed
12) Schmidt G, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet. 1999 ; 353 : 1390-6.
PubMed
13) Malik M. Heart rate variability and baroreflex sensitivity. In : Zipes DP, Jalife J, editors. Cardiac Electrophysiology : From Cell to Bedside (4th ed). Philadelphia : Saunders ; 2004. p. 823-30.
 
14) Miyakoshi M, et al. Quantitative assessment of cibenzoline administration for vagally mediated paroxysmal atrial fibrillation using frequency-domain heart rate variability analysis. J Cardiol. 2009 ; 54 : 86-92.
PubMed
15) Ishiguro H, et al. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 ; 49 : 281-93.
PubMed
16) Elvan A, et al. Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation. 1995 ; 91 : 2235-44.
PubMed
17) Schauerte P, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation. 2000 ; 102 : 2774-80.
PubMed
18) Pappone C, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004 ; 109 : 327-34.
PubMed
19) Bourke T, et al. Neuraxial modulation for refractory ventricular arrhythmias : value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. Circulation. 2010 ; 121 : 2255-62.
PubMed
20) Ajijola OA, et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll Cardiol. 2012 ; 59 : 91-2.
 
21) Vaseghi M, et al. Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol. 2017 ; 69 : 3070-80.
PubMed
P.97 掲載の参考文献
1) Marrouche NF, et al ; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018 ; 378 : 417-27.
PubMed
2) Nagai T, et al ; JASPER Investigators. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction- a report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. Circ J. 2018 ; 82 : 1534-45.
PubMed
3) Sanna T, et al ; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 ; 370 : 2478-86.
PubMed
4) Senoo K, et al. Distribution of first-detected atrial fibrillation patients without structural heart diseases in symptom classifications. Circ J. 2012 ; 76 : 1020-3.
PubMed
5) Esato M, et al. Clinical impact of asymptomatic presentation status in patients with paroxysmal and sustained atrial fibrillation : The Fushimi AF Registry. Chest. 2017 ; 152 : 1266-75.
PubMed
6) Disertori M, et al. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J. 2011 ; 162 : 382-9.
PubMed
7) Boriani G, et al. Asymptomatic atrial fibrillation : clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015 ; 128 : 509-18. e2.
 
8) Piccini JP, et al ; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Differences in clinical and functional outcomes of atrial fibrillation in women and men : two-year results from the ORBIT-AF Registry. JAMA Cardiol. 2016 ; 1 : 282-91.
PubMed
9) Lowres N, et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost. 2013 ; 110 : 213-22.
PubMed
10) Glotzer TV, et al ; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke : report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003 ; 107 : 1614-9.
PubMed
11) Healey JS, et al ; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 ; 366 : 120-9.
PubMed
12) Boriani G, et al. Device-detected atrial fibrillation and risk for stroke : an analysis of > 10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014 ; 35 : 508-16.
PubMed
13) Van Gelder IC, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017 ; 38 : 1339-44.
PubMed
14) Brambatti M, et al ; ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014 ; 129 : 2094-9.
PubMed
15) Kohno R, et al. Ambulatory electrocardiogram monitoring devices for evaluating transient loss of consciousness or other related symptoms. J Arrhythm. 2017 ; 33 : 583-9.
PubMed
16) Tsukada YT, et al. Validation of wearable textile electrodes for ECG monitoring. Heart Vessels. 2019 [Epub ahead of print]
 
17) Steinhubl SR, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation : The mSToPS Randomized Clinical Trial. JAMA. 2018 ; 320 : 146-55.
PubMed
18) Brasier N, et al. Detection of atrial fibrillation with a smartphone camera : first prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace. 2019 ; 21 : 41-7.
PubMed
19) Kashiwa A, et al. Performance of an atrial fibrillation detection algorithm using continuous pulse wave monitoring. Ann Noninvasive Electrocardiol. 2019 ; 24 : e12615.
PubMed
20) Tison GH, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol. 2018 ; 3 : 409-16.
PubMed
P.109 掲載の参考文献
1) Atarashi H, et al ; J-RHYTHM Registry Investigators. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation -The J-RHYTHM Registry study design. J Cardiol. 2011 ; 57 : 95-9.
 
2) Atarashi H, et al ; J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation : a report from the J-RHYTHM Registry. Circ J. 2011 ; 75 : 1328-33.
 
3) Akao M, et al ; Fushimi AF Registry Investigators. Current status of clinical background of patients with atrial fibrillation in a community-based survey : the Fushimi AF Registry. J Cardiol. 2013 ; 61 : 260-6.
 
4) Inoue H, et al ; J-RHYTHM Registry Investigators. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation : results of the J-RHYTHM Registry. Circ J. 2013 ; 77 : 2264-70.
 
5) Akao M, et al ; Fushimi AF Registry Investigators. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014 ; 78 : 2166-72.
PubMed
6) J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. -Subanalysis of the J-RHYTHM Registry-. Circ J. 2011 ; 75 : 2357-62.
 
7) Okumura K, et al ; J-RHYTHM Registry Investigators. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation : an analysis of the J-RHYTHM Registry. Circ J. 2014 ; 78 : 1593-9.
 
8) Chishaki A, et al ; J-RHYTHM Registry Investigators. Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry. Thromb Res. 2015 ; 136 : 267-73.
 
9) 小谷英太郎, 他. 心房細動に対するワルファリン療法における日本人の至適INR─J-RHYTHM Registryからの報告-. 心電図. 2013 ; 33 : 25-31.
Medical*Online
10) Yamashita T, et al ; J-RHYTHM Registry Investigators. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients : a J-RHYTHM Registry analysis. J Cardiol. 2015 ; 65 : 175-7.
 
11) Inoue H, et al ; J-RHYTHM Registry Investigators. Time in therapeutic range and disease outcomes in elderly Japanese patients with nonvalvular atrial fibrillation. Circ J. 2018 ; 82 : 2510-7.
PubMed
12) Suzuki S, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 2015 ; 79 : 432-8.
 
13) Iguchi M, et al. Incidence and risk factors of stroke or systemic embolism in patients with atrial fibrillation and heart failure- The Fushimi AF Registry. Circ J. 2018 ; 82 : 1327-35.
 
14) Kodani E, et al ; J-RHYTHM Registry Investigators. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation : A subanalysis of the J-RHYTHM Registry. J Am Heart Assoc. 2016 ; 5. pii : e004075.
 
15) Ishii M, et al. Relationship of hypertension and systolic blood pressure with the risk of stroke or bleeding in patients with atrial fibrillation : The Fushimi AF Registry. Am J Hypertens. 2017 ; 30 : 1073-82.
 
16) Kodani E, et al ; J-RHYTHM Registry Investigators. Use of warfarin in elderly patients with non-valvular atrial fibrillation -Subanalysis of the J-RHYTHM Registry-. Circ J. 2015 ; 79 : 2345-52.
 
17) Yamashita Y, et al. Clinical Characteristics and Outcomes in Extreme Elderly (Age ? 85 Years) Japanese Patients With Atrial Fibrillation : The Fushimi AF Registry. Chest. 2016 ; 149 : 401-12.
PubMed
18) Senoo K, et al. Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. Heart. 2016 ; 102 : 1878-82.
PubMed
19) Kumagai N, et al ; J-RHYTHM Registry Investigators. Effect of addition of a statin to warfarin on thromboembolic events in Japanese patients with nonvalvular atrial fibrillation and diabetes mellitus. Am J Cardiol. 2017 ; 120 : 230-5.
PubMed
20) Kodani E, et al ; J-RHYTHM Registry Investigators. Secondary prevention of stroke with warfarin in patients with non-valvular atrial fibrillation : Subanalysis of the J-RHYTHM Registry. J Stroke Cerebrovasc Dis. 2016 ; 25 : 585-99.
 
21) Ogawa H, et al. Clinical features and prognosis in patients with atrial fibrillation and prior stroke : Comparing the Fushimi and Darlington AF Registries. EBioMedicine. 2017 ; 18 : 199-203.
PubMed
22) Inoue H, et al ; J-RHYTHM Registry Investigators. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014 ; 113 : 957-62.
PubMed
23) Ogawa H, et al ; Fushimi AF Registry Investigators. Sex-related differences in the clinical events of patients with atrial fibrillation- The Fushimi AF Registry. Circ J. 2017 ; 81 : 1403-10.
PubMed
24) Tomita H, et al ; J-RHYTHM Registry Investigators. Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation-Subanalysis of the J-RHYTHM Registry. Circ J. 2015 ; 79 : 1719-26.
 
25) Inoue H, et al ; Research Group for Antiarrhythmic Drug Therapy. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am J Cardiol. 2000 ; 86 : 852-5.
 
26) Takabayashi K, et al. Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation : The Fushimi Atrial Fibrillation Registry. Stroke. 2015 ; 46 : 3354-61.
 
27) Esato M, et al. Clinical impact of asymptomatic presentation status in patients with paroxysmal and sustained atrial fibrillation : The Fushimi AF Registry. Chest. 2017 ; 152 : 1266-75.
PubMed
28) Ogawa H, et al ; Fushimi AF Registry Investigators. Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. Stroke. 2018 ; 49 : 2301-8.
PubMed
29) An Y, et al. Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy : the Fushimi AF Registry. Heart Vessels. 2018 ; 33 : 1534-46.
PubMed
30) Hamatani Y, et al. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci Rep. 2016 ; 6 : 31042.
PubMed
31) Hamatani Y, et al. Low body weight is associated with the incidence of stroke in atrial fibrillation patients-Insight from the Fushimi AF Registry. Circ J. 2015 ; 79 : 1009-17.
PubMed
32) Inoue H, et al ; J-RHYTHM Registry Investigators. Impact of body mass index on the prognosis of Japanese patients with non-valvular atrial fibrillation. Am J Cardiol. 2016 ; 118 : 215-21.
PubMed
33) Abe M, et al. Relation of stroke and major bleeding to creatinine clearance in patients with atrial fibrillation (from the Fushimi AF Registry). Am J Cardiol. 2017 ; 119 : 1229-37.
PubMed
34) Yamashita Y, et al. Clinical characteristics and outcomes of dialysis patients with atrial fibrillation : the Fushimi AF Registry. Heart Vessels. 2016 ; 31 : 2025-34.
PubMed
35) Kodani E, et al ; J-RHYTHM Registry Investigators. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation : a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes. 2018 ; 4 : 59-68.
 
36) Inoue H, et al ; J-RHYTHM Registry Investigators. Renal dysfunction affects anticoagulation control with warfarin and outcomes in Japanese elderly patients with non-valvular atrial fibrillation. Circ J. 2018 ; 82 : 2277-83.
PubMed
37) Ogawa H, et al. Antiplatelet therapy in Japanese patients with atrial fibrillation without oral anticoagulants : Pooled analysis of Shinken Database, J-RHYTHM registry and Fushimi AF registry. Int J Cardiol. 2015 ; 190 : 344-6.
PubMed
38) Watanabe E, et al ; J-RHYTHM Registry Investigators. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation : Insights from the J-RHYTHM Registry. Int J Cardiol. 2016 ; 212 : 311-7.
 
39) Masunaga N, et al ; Fushimi AF Registry Investigators. Current status, time trends and outcomes of combination therapy with oral anticoagulant and antiplatelet drug in patients with atrial fibrillation- The Fushimi AF Registry. Circ J. 2018 ; 82 : 2983-91.
PubMed
40) Inoue H, et al ; J-RHYTHM Registry Investigators. Regional differences in frequency of warfarin therapy and thromboembolism in Japanese patients with non-valvular atrial fibrillation-Analysis of the J-RHYTHM Registry. Circ J. 2016 ; 80 : 1548-55.
 
41) Kodani E, et al ; J-RHYTHM Registry Investigators. Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation : Subanalysis of the J-RHYTHM Registry. Circ J. 2015 ; 79 : 325-30.
 
42) Kodani E, et al ; J-RHYTHM Registry Investigators. Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation- Results of the J-RHYTHM Registry 2. Circ J. 2016 ; 80 : 843-51.
 
43) Yamashita Y, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients- Fushimi AF Registry. Circ J. 2017 ; 81 : 1278-85.
PubMed
44) Okumura Y, et al ; The Sakura AF Registry Investigators. Current use of direct oral anticoagulants for atrial fibrillation in Japan : Findings from the SAKURA AF Registry. J Arrhythm. 2017 ; 33 : 289-96.
PubMed
45) Okumura Y, et al ; The Sakura AF Registry Investigators. Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation-Findings From the SAKURA AF Registry. Circ J. 2018 ; 82 : 2500-9.
 
46) An Y, et al. Causes of death in Japanese patients with atrial fibrillation : The Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes. 2019 ; 5 : 35-42.
PubMed
47) Hamatani Y, et al. Predictors for stroke and death in non-anticoagulated Asian patients with atrial fibrillation : The Fushimi AF Registry. PLoS One. 2015 ; 10 : e0142394.
PubMed
48) Kuronuma K, et al ; The Sakura AF Registry Investigators. Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation : A SAKURA AF Registry substudy. J Cardiol. 2019 ; 73 : 210-7.
 
P.125 掲載の参考文献
1) Kodani E, et al ; J-RHYTHM Registry Investigators. Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation -results of the J-RHYTHM Registry 2. Circ J. 2016 ; 80 : 843-51.
 
2) Yamashita Y, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients-Fushimi AF Registry. Circ J. 2017 ; 81 : 1278-85.
PubMed
3) Marzec LN, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017 ; 69 : 2475-84.
PubMed
4) Apenteng PN, et al ; UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation : findings from the GARFIELD-AF registry. BMJ Open. 2018 ; 8 : e018905.
 
5) Gadsboll K, et al. Increased use of oral anticoagulants in patients with atrial fibrillation : temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017 ; 38 : 899-906.
PubMed
6) Cowan JC, et al. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018 ; 39 : 2975-83.
PubMed
7) Okumura Y, et al ; The Sakura Af Registry Investigators. Current use of direct oral anticoagulants for atrial fibrillation in Japan : Findings from the SAKURA AF Registry. J Arrhythm. 2017 ; 33 : 289-96.
PubMed
8) Steinberg BA, et al ; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes : The ORBIT-AF II Registry. J Am Coll Cardiol. 2016 ; 68 : 2597-604.
PubMed
9) Graham DJ, et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019 ; 132 : 596-604. e11.
 
10) Shore S, et al. Adherence to dabigatran therapy and longitudinal patient outcomes : insights from the veterans health administration. Am Heart J. 2014 ; 167 : 810-7.
PubMed
11) Piccini JP, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016 ; 133 : 352-60.
PubMed
12) Quinn GR, et al. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation. 2017 ; 135 : 208-19.
PubMed
13) 総務省. スマートフォン経済の現在と将来. 平成29年版情報通信白書. 2017. http://www.soumu.go.jp/johotsusintokei/whitepaper/ja/h29/html/nc110000.html, (閲覧 : 2019-03-11)
 
14) 総務省. 平成28年版情報通信白書. 2016. http://www.soumu.go.jp/johotsusintokei/whitepaper/ja/h28/pdf/index.html, (閲覧 : 2019-03-11)
 
15) Inoue H, et al. Prospective observational study in elderly patients with non-valvular atrial fibrillation : rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. J Cardiol. 2018 ; 72 : 300-6.
PubMed
16) Okumura K, et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies : rationale and design of the ELDERCARE-AF study. Am Heart J. 2017 ; 194 : 99-106.
PubMed
17) Aonuma K, et al. Percutaneous WATCHMAN left atrial appendage closure for Japanese patients with nonvalvular atrial fibrillation at increased risk of thromboembolism-first results from the SALUTE Trial. Circ J. 2018 ; 82 : 2946-53.
PubMed
18) Ohtsuka T, et al. Thoracoscopic stapler-and-loop technique for left atrial appendage closure in nonvalvular atrial fibrillation : mid-term outcomes in 201 patients. Heart Rhythm. 2018 ; 15 : 1314-20.
PubMed
P.135 掲載の参考文献
1) Haissaguerre M, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 ; 339 : 659-66.
PubMed
2) 循環器病の診断と治療に関するガイドライン (2010-2011年度合同研究班報告). カテーテルアブレーションの適応と手技に関するガイドライン. http://www.j-circ. or.jp/guideline/pdf/JCS2012_okumura_h.pdf, (閲覧 : 2019-3-15)
 
3) Calkins H, et al ; Document Reviewers. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018 ; 20 : e1-e160.
 
4) Marrouche NF, et al ; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 ; 378 : 417-27.
PubMed
5) January CT,et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of Patients with atrial fibrillation. Circulation. 2019 [Epub ahead of print]
 
6) Takahashi A, et al. Efficacy and Feasibility of Extensive Ablation Encircling Two Ipsilateral Pulmonary Veins in Patients with Paroxysmal Atrial Fibrillation. Circ J. 2003 ; 67 (Suppl 1) : 342.
 
7) Ouyang F, et al. Complete isolation of left atrium surrounding the pulmonary veins : new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation. 2004 ; 110 : 2090-6.
PubMed
8) Goya M, et al. Electroanatomic mapping and catheter ablation of breakthroughs from the right atrium to the superior vena cava in patients with atrial fibrillation. Circulation. 2002 ; 106 : 1317-20.
 
9) Kurotobi T, et al. Multiple arrhythmogenic foci associated with the development of perpetuation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 ; 3 : 39-45.
PubMed
10) Neuzil P, et al. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment : results from the EFFICAS I study. Circ Arrhythm Electrophysiol. 2013 ; 6 : 327-33.
PubMed
11) Phlips T, et al. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation : the role of interlesion distance, ablation index, and contact force variability in the 'CLOSE' -protocol. Europace. 2018 ; 20 : f419-27.
PubMed
12) Mattia L, et al. Prospective Evaluation of Lesion Index-Guided Pulmonary Vein Isolation Technique in Patients with Paroxysmal Atrial Fibrillation : 1-year Follow-Up. J Atr Fibrillation. 2018 ; 10 : 1858.
PubMed
13) Winkle RA, et al. Atrial fibrillation ablation using very short duration 50 W ablations and contact force sensing catheters. J Interv Card Electrophysiol. 2018 ; 52 : 1-8.
PubMed
14) Leshem E, et al. High-Power and Short-Duration Ablation for Pulmonary Vein Isolation : Biophysical Characterization. JACC Clin Electrophysiol. 2018 ; 4 : 467-79.
PubMed
15) Packer D, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation : first results of the North American Arctic Front STOP-AF pivotal trial. J Am Coll Cardiol 2010 ; 55 : e3015-6.
 
16) Kuck KH, et al ; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 ; 374 : 2235-45.
 
17) Straube F, et al ; FREEZE Cohort Investigators. First-line catheter ablation of paroxysmal atrial fibrillation : outcome of radiofrequency vs. cryoballoon pulmonary vein isolation. Europace. 2016 ; 18 : 368-75.
PubMed
18) Nanbu T, et al. A relation between ablation area and outcome of ablation using 28-mm cryoballon ablation : Importance of carina region. J Cardiovasc Electrophysiol. 2018 ; 29 : 1221-9.
PubMed
19) Kajiyama T, et al. Anatomic Parameters Predicting Procedural Difficulty and Balloon Temperature Predicting Successful Applications in Individual Pulmonary Veins During 28-mm Second-Generation Cryoballoon Ablation. JACC Clin Electrophysiol. 2017 ; 3 : 580-8.
PubMed
20) Narui R, et al. Incidence and Factors Associated With the Occurrence of Pulmonary Vein Narrowing After Cryoballoon Ablation. Circ Arrhythm Electrophysiol. 2017 ; 10 : pii : e004588.
 
21) 佐竹修太郎, 他. 心房細動ホットバルーンアブレーション. 杉本恒明 (監), 井上博 (編), 不整脈2017. 大阪 : メディカルレビュー社 ; 2017, p. 103-13.
 
22) Sohara H, et al. HotBalloon Ablation of the Pulmonary Veins for Paroxysmal AF : A Multicenter Randomized Trial in Japan. J Am Coll Cardiol. 2016 ; 68 : 2747-57.
PubMed
23) Nagashima K et al. Hot Balloon Versus Cryoballoon Ablation for Atrial Fibrillation : Lesion Characteristics and Middle-Term Outcomes. Circ Arrhythm Electrophysiol. 2018 ; 11 : e005861.
PubMed
24) Miyazaki S, et al. Sequential biatrial linear defragmentation approach for persistent atrial fibrillation. Heart Rhythm. 2013 ; 10 : 338-46.
PubMed
25) Miyazaki S, et al. Five-year follow-up outcome after catheter ablation of persistent atrial fibrillation using a sequential biatrial linear defragmentation approach : What does atrial fibrillation termination during the procedure imply? Heart Rhythm. 2017 ; 14 : 34-40.
PubMed
26) Verma A, et al ; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015 ; 372 : 1812-22.
PubMed
27) Santangeli P, et al. Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial fibrillation. Heart Rhythm. 2016 ; 13 : 374-82.
PubMed
28) Miyazaki S, et al. Durability of cryothermal pulmonary vein isolation-Creating contiguous lesions is necessary for persistent isolation. Int J Cardiol. 2016 ; 220 : 395-9.
PubMed
29) Akkaya E, et al. Second-generation cryoballoon ablation for treatment of persistent atrial fibrillation : Three-year outcome and predictors of recurrence after a single procedure. J Cardiovasc Electrophysiol. 2018 ; 29 : 38-45.
PubMed
30) Omran H, et al. Second generation cryoballoon ablation for persistent atrial fibrillation : an updated metaanalysis. Clin Res Cardiol. 2018 ; 107 : 182-92.
PubMed
31) Aryana A, et al. Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation : A multicenter experience. Heart Rhythm. 2018 ; 15 : 1121-9.
PubMed
32) Sohara H, et al. Feasibility of the radiofrequency hot balloon catheter for isolation of the posterior left atrium and pulmonary veins for the treatment of atrial fibrillation. Circ Arrhythm Electrophysiol. 2009 ; 2 : 225-32.
PubMed
P.148 掲載の参考文献
1) Calkins H, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 ; 14 : e275-e444.
PubMed
2) Inoue K, et al ; Japanese Heart Rhythm Society Members. Current status of catheter ablation of atrial fibrillation in Japan : Summary of the 4th survey of the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). J Cardiol. 2016 ; 68 : 83-8.
PubMed
3) Hamaya R, et al. Management of cardiac tamponade in catheter ablation of atrial fibrillation : single-centre 15 year experience on 5222 procedures. Europace. 2018 ; 20 : 1776-82.
PubMed
4) Schmidt M, et al. German ablation registry : Cryoballoon vs. radiofrequency ablation in paroxysmal atrial fibrillation-One-year outcome data. Heart Rhythm. 2016 ; 13 : 836-44.
PubMed
5) Quallich SG, et al. Optimal contact forces to minimize cardiac perforations before, during, and/or after radiofrequency or cryothermal ablations. Heart Rhythm. 2015 ; 12 : 291-6.
 
6) Pollack CV Jr, et al. Idarucizumab for Dabigatran Reversal-Full Cohort Analysis. N Engl J Med. 2017 ; 377 : 431-41.
PubMed
7) Liu Y, et al. Incidence and clinical characteristics of postcardiac injury syndrome complicating cardiac perforation caused by radiofrequency catheter ablation for cardiac arrhythmias. Int J Cardiol. 2013 ; 168 : 3224-9.
PubMed
8) Sanchez-Quintana D, et al. Anatomic relations between the esophagus and left atrium and relevance for ablation of atrial fibrillation. Circulation. 2005 ; 112 : 1400-5.
PubMed
9) John RM, et al. Atrioesophageal fistula formation with cryoballoon ablation is most commonly related to the left inferior pulmonary vein. Heart Rhythm. 2017 ; 14 : 184-9.
 
10) Miyazaki S, et al. Esophagus-Related Complications During Second-Generation Cryoballoon Ablation-Insight from Simultaneous Esophageal Temperature Monitoring from 2 Esophageal Probes. J Cardiovasc Electrophysiol. 2016 ; 27 : 1038-44.
PubMed
11) Miyazaki S, et al. Gastric hypomotility after second-generation cryoballoon ablation-Unrecognized silent nerve injury after cryoballoon ablation. Heart Rhythm. 2017 ; 14 : 670-7.
PubMed
12) Di Biase L, et al. Esophageal capsule endoscopy after radiofrequency catheter ablation for atrial fibrillation : documented higher risk of luminal esophageal damage with general anesthesia as compared with conscious sedation. Circ Arrhythm Electrophysiol. 2009 ; 2 : 108-12.
PubMed
13) Shah D, et al. Acute pyloric spasm and gastric hypomotility : an extracardiac adverse effect of percutaneous radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol. 2005 ; 46 : 327-30.
PubMed
14) Miyazaki S, et al. Factors associated with periesophageal vagal nerve injury after pulmonary vein antrum isolation. J Am Heart Assoc. 2014 ; 3 : e001209.
PubMed
15) Hasegawa K, et al. Gastric Hypomotility After Luminal Esophageal Temperature Guided Second-Generation Cryoballoon Pulmonary Vein Isolation. Circ Arrhythm Electrophysiol. 2018 ; 11 : e006691.
PubMed
16) Kuwahara T, et al. Clinical characteristics and management of periesophageal vagal nerve injury complicating left atrial ablation of atrial fibrillation : lessons from eleven cases. J Cardiovasc Electrophysiol. 2013 ; 24 : 847-51.
 
17) Miyazaki S, et al. Prevalence and clinical outcome of phrenic nerve injury during superior vena cava isolation and circumferential pulmonary vein antrum isolation using radiofrequency energy. Am Heart J. 2014 ; 168 : 846-53.
PubMed
18) Miyazaki S, et al. Characteristics of Phrenic Nerve Injury During Pulmonary Vein Isolation Using a 28-mm Second-Generation Cryoballoon and Short Freeze Strategy. J Am Heart Assoc. 2018 ; 7 : pii : e008249.
 
19) Franceschi F, et al. Phrenic nerve monitoring with diaphragmatic electromyography during cryoballoon ablation for atrial fibrillation : the first human application. Heart Rhythm. 2011 ; 8 : 1068-71.
PubMed
20) 日本循環器学会, 他. 不整脈非薬物治療ガイドライン (2018年改訂版). 2019. http://www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf, (閲覧 : 2019-05-21)
 
21) Calkins H, et al ; RE-CIRCUIT Investigators. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017 ; 376 : 1627-36.
PubMed
22) Di Biase L, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management : results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014 ; 129 : 2638-44.
PubMed
23) Kuwahara T, et al. Clinical characteristics of massive air embolism complicating left atrial ablation of atrial fibrillation : lessons from five cases. Europace. 2012 ; 14 : 204-8.
PubMed
24) Miyazaki S, et al. Thromboembolic Risks of the Procedural Process in Second-Generation Cryoballoon Ablation Procedures : Analysis From Real-Time Transcranial Doppler Monitoring. Circ Arrhythm Electrophysiol. 2017 ; 10 : pii : e005612.
 
25) Miyazaki S, et al. Silent cerebral events/lesions after second-generation cryoballoon ablation : How can we reduce the risk of silent strokes? Heart Rhythm. 2019 ; 16 : 41-8.
PubMed
26) Hasegawa K, et al. Late-onset lethal arrhythmia after catheter ablation. J Cardiovasc Electrophysiol. 2018 ; 29 : 485-6.
PubMed
27) Holmes DR Jr, et al. Pulmonary vein stenosis complicating ablation for atrial fibrillation : clinical spectrum and interventional considerations. JACC Cardiovasc Interv. 2009 : 2 ; 267-76.
PubMed
28) Khairy P, et al. Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation. Circulation 2003 ; 107 : 2045-50.
PubMed
29) Miyazaki S, et al. Does second-generation cryoballoon ablation using the current single short freeze strategy produce pulmonary vein stenosis? Int J Cardiol. 2018 ; 272 : 175-8.
PubMed
P.160 掲載の参考文献
1) Inoue H, et al. Intracoronary ethyl alcohol or phenol injection ablates aconitine-induced ventricular tachycardia in dogs. J Am Coll Cardiol. 1987 ; 10 : 1342-9.
PubMed
2) Brugada P, et al. Transcoronary chemical ablation of ventricular tachycardia. Circulation. 1989 ; 79 : 475-82.
PubMed
3) Okishige K, et al. Suppression if incessant polymorphic ventricular tachycardia by selective intracoronary ethanol infusion. PACE. 1991 ; 14 : 188-95.
PubMed
4) Berte B, et al. A case of incessant VT from an intramural septal focus : Ethanol or bipolar ablation? Heart Rhythm Case Reports. 2015 ; 1 : 89-94.
PubMed
5) Kreidieh B, et al. Retrograde coronary venous ethanol infusion for ablation of refractory ventricular tachycardia. Circ Arrhythm Electrophsyiol. 2016 ; 9 : e004352.
 
6) Baez-Escudero JL, et al. Ethanol infusion in the vein of Marshall facilitates mitral isthmus ablation. Heart Rhythm. 2012 ; 9 : 1207-15.
PubMed
7) Sacher F, et al. Transcoronary ethanol ventricular tachycardia ablation in the modern electrophysiology era. Heart Rhythm. 2008 ; 5 : 62-8.
PubMed
8) Tokuda M, et al. Transcoronary ethanol ablation for recurrent ventricular tachycardia after failed catheter ablation. Corc Arrhythm Electrophysiol. 2011 ; 4 : 889-96.
 
9) Strickiberger SA, et al. A comparative study of intracoronary iced saline versus intracoronary antiarrhythmic drugs to identify the ventricular tachycardia-related artery. J Cardiovasc Electrophysiol. 1992 ; 3 : 199-208.
 
10) Wright KN, et al. Retrograde coronary venous infusion of ethanol for ablation of canine ventricular myocardium. J Cardiovasc Electrophysiol. 1998 ; 9 : 976-84.
PubMed
11) Yamada T, et al. Idiopathic ventricular arrhythmias originating from the left ventricular summit : anatomical concepts relevant to ablation. Circ Arrhythm Electrophysiol. 2010 ; 3 : 616-23.
 
12) Komatsu Y, et al. Idiopathic ventricular arrhythmias originating from the vicinity of the communicating vein of cardiac venous systems at the left ventricular summit. Circ Arrhythm Electrophysiol. 2018 ; 11 : e005386.
PubMed
13) Okishige K, et al. Chemical ablation of ventricular tachycardia arising from the left ventricular summit. Clinical Case Repor (t in press) DIO : 10.1002/ccr3.1397
 
14) Hwang C, et al. Vein of Marshall cannulation for the analysis of electrical activity in patients with focal atrial fibrillation. Circulation. 2000 ; 101 : 1503-5.
PubMed
15) Hwang C, et al. Ligament of Marshall : Why it is important for atrial fibrillation ablation. Heart Rhythm. 2009 ; 6 : S35-40.
PubMed
16) Keida T, et al. Elimination of non-pulmonary vein ectppy by ethanol infusion in the vein of Marshall. Heart Rhythm. 2013 ; 10 : 1354-6.
PubMed
17) Jais P, et al. Tedchnique and results of linear ablation at the mitral isthmus. Circulation. 2004 ; 110 : 2996-3002.
PubMed
18) Knecht S, et al. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. Eur Heart J. 2008 ; 29 : 2359-66.
PubMed
19) Ulphani JS, et al. The ligament of Marshall as a parasympathetic conduit. Am J Physiol. 2007 ; 293 : H1629-35.
 
20) Baez-Escudero JL, et al. Ethanol infusion in the vein of Marshall leads to parasympathetic denervation of the human left atrium. J Am Coll Cardiol. 2014 ; 63 : 1892-901.
PubMed
P.170 掲載の参考文献
1) Boineau JP, et al. Rational for a direct surgical approach to control ventricular arrhythmias : relation of specific intraoperative techniques to mechanism and location of arrhythmic circuit. Am J Cardiol. 1982 ; 49 : 381-96.
 
2) Miller JM, et al. Pattern of endocardial activation during sustained ventricular tachycardia. J Am Coll Cardiol. 1985 ; 6 : 1280-7.
PubMed
3) Ostermeyer J, et al. Direct operations for the management of life threatening ischemic ventricular tachycardia. J Thorac Cardiovasc Surg. 1987 ; 94 : 848-65.
PubMed
4) Caceres J, et al. Efficacy of cryosurgery alone for refractory monomorphic sustained ventricular tachycardia due to inferior wall infarction. J Am Coll Cardiol. 1988 ; 11 : 1254-9.
PubMed
5) Selle JG, et al. Successful clinical laser ablation of ventricular tachycardia : a promising new therapeutic method. Ann Thorac Surg. 1986 ; 42 : 380-4.
PubMed
6) Hargrove WC 3rd, et al. Surgical decisions in the management of sudden cardiac death and malignant ventricular arrhythmias. Subendocardial resection, the automatic internal defibrillator, or both. J Thorac Cardiovasc Surg. 1989 ; 97 : 923-8.
PubMed
7) de Bakker JM, et al. Ventricular tachycardia in the inracted, Langendorff-perfused human heart : role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol. 1990 ; 15 : 1594-607.
PubMed
8) de Bakker JM, et al. Macroreentry in the infracted human heart : The mechanism of ventricular tachycardias with a "focal" activation pattern. J Am Coll Cardiol. 1991 ; 18 : 1005-14.
 
9) de Bakker JM, et al. Slow conduction in the infracted human heart. 'Zigzag' course of activation. Circulation. 1993 ; 88 : 915-26.
 
10) Fitzgerald DM, et al. Electrogram patterns predicting successful catheter ablation of ventricular tachycardia. Circulation. 1988 ; 77 : 806-14.
PubMed
11) Morady F, et al. Identification and catheter ablation of a zone of slow conduction in the reentrant circuit of ventricular tachycardia in humans. J Am Coll Cardiol. 1988 ; 11 : 775-82.
PubMed
12) Stevenson WG, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation. 1993 ; 88 : 1647-70.
PubMed
13) Marchlinski FE, et al. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000 ; 101 : 1288-96.
PubMed
14) Soejima K, et al. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy : the importance of low-voltage scars. J Am Coll Cardiol. 2004 ; 43 : 1834-42.
PubMed
15) Reddy VY, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007 ; 357 : 2657-65.
PubMed
16) Jais P, et al. Elimination of local abnormal ventricular activities : a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012 ; 125 : 2184-96.
PubMed
17) Nakagawa H, et al. Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. Circulation. 1995 ; 91 : 2264-73.
 
18) Nakagawa H, et al. Locations of high contact force during left atrial mapping in atrial fibrillation patients : electrogram amplitude and impedance are poor predictors of electrode-tissue contact force for ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2013 ; 6 : 746-53.
PubMed
19) Ikeda A, et al. Relationship between catheter contact force and radiofrequency lesion size and incidence of steam pop in the beating canine heart : electrogram amplitude, impedance, and electrode temperature are poor predictors of electrode-tissue contact force and lesion size. Circ Arrhythm Electrophysiol. 2014 ; 7 : 1174-80.
PubMed
20) Sosa E, et al. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol. 1996 ; 7 : 531-6.
 
21) Hutchinson MD, et al. Endocardial unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2011 ; 4 : 49-55.
PubMed
22) Aagaard P, et al. Remote magnetic navigation : a Focus on catheter ablation of ventricular arrhythmias. J Cardiovasc Electrophysiol. 2016 ; 27 (Suppl. 1) : S38-44.
 
23) Nakagawa H, et al. Rapid high resolution electroanatomical mapping : evaluation of a new system in a canine atrial linear lesion model. Circ Arrhythm Electrophysiol. 2012 ; 5 : 417-24.
 
24) Josephson ME, et al. Substrate mapping for ventricular tachycardia : assumptions and misconceptions. JACC Clin Electrophysiol. 2015 ; 1 : 341-52.
PubMed
25) Anter E, et al. High-resolution mapping of postinfarction reentrant ventricular tachycardia : electrophysiological characterization of the circuit. Circulation. 2016 ; 134 : 314-27.
PubMed
26) Linton NW, et al. Cardiac ripple mapping : a novel three-dimensional visualization method for use with electroanatomic mapping of cardiac arrhythmias. Heart Rhythm. 2009 ; 6 : 1754-62.
PubMed
27) Luther V, et al. A prospective study of ripple mapping the post-infarct ventricular scar to guide substrate ablation for ventricular tachycardia. Circ Arrhythm Electrophysiol. 2016 ; 9 : pii : e004072.
 
28) Sapp JL, et al. Large radiofrequency ablation lesions can be created with a retractable infusion-needle catheter. J Cardiovasc Electrophysiol. 2006 ; 17 : 657-61.
PubMed
P.182 掲載の参考文献
1) Purkinje JE. Mikroscopisch-neurologische Beobachtungen. Arch Anat Physiol wiss Med. 1845 ; 12 : 281-95.
 
2) Tawara S. Das Reizleitungssystem des Saugetierherzens. Eine anatomisch-histologische studie uber das Atrioventricularbundel und die Purkinjeschen Faden. Jena, Gustav Fischer, 1906. (Tawara S. The conduction system of the mammalian heart. Suma K, Shimada M, trans. London, UK : Imperial College Press, 2000.)
 
3) Nogami A. Idiopathic left ventricular tachycardia : assessment and treatment. Card Electrophysiol Rev. 2002 ; 6 : 448-57.
PubMed
4) Nogami A, et al. Ablation of idiopathic left and right ventricular and fascicular tachycardias. In : Huang SKS, Miller JM editors. Catheter ablation of cardiac arrhythmias (4th ed). Philadelphia : Elsevier ; 2019. pp. 467-509.
 
5) Nogami A. Purkinje-related arrhythmias part I : monomorphic ventricular tachycardias. Pacing Clin Electrophysiol. 2011 ; 34 : 624-50.
PubMed
6) Nogami A. Purkinje-related arrhythmias part II : polymorphic ventricular tachycardia and ventricular fibrillation. Pacing Clin Electrophysiol. 2011 ; 34 : 1034-49.
PubMed
7) Zipes DP, et al. Atrial induction of ventricular tachycardia : reentry versus triggered automaticity. Am J Cardiol. 1979 ; 44 : 1-8.
PubMed
8) Belhassen B, et al. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J. 1981 ; 46 : 679-82.
PubMed
9) Ohe T, et al. Idiopathic sustained left ventricular tachycardia : clinical and electrophysiological characteristics. Circulation. 1988 ; 77 : 560-8.
PubMed
10) Nogami A, et al. Verapamil-sensitive left anterior fascicular ventricular tachycardia : results of radiofrequency ablation in six patients. J Cardiovasc Electrophysiol. 1998 ; 9 : 1269-78.
PubMed
11) Talib AK, et al. Verapamil-sensitive upper septal idiopathic left ventricular tachycardia : Prevalence, mechanism, and electrophysiological characteristics. JACC Clin Electrophysiol. 2015 ; 1 : 369-80.
PubMed
12) Hayashi M, et al. Novel mechanism of postinfarction ventricular tachycardia originating in surviving left posterior Purkinje fibers. Heart Rhythm. 2006 ; 3 : 908-18.
PubMed
13) Nakagawa H, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation. 1993 ; 88 : 2607-17.
PubMed
14) Tsuchiya T, et al. Significance of late diastolic potential preceding Purkinje potential in verapamil-sensitive idiopathic left ventricular tachycardia. Circulation. 1999 ; 99 : 2408-13.
PubMed
15) Aiba T, et al. Mid-diastolic potential is related to the reentrant circuit in a patient with verapamil-sensitive idiopathic left ventricular tachycardia. J Cardiovasc Electrophysiol. 1998 ; 9 : 1004-7.
 
16) Nogami A, et al. Demonstration of diastolic and presystolic Purkinje potential as critical potentials on a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000 ; 36 : 811-23.
PubMed
17) Tada H, et al. Retrograde Purkinje potential activation during sinus rhythm following catheter ablation of idiopathic left ventricular tachycardia. J Cardiovasc Electrophysiol. 1998 ; 9 : 1218-24.
PubMed
18) Morishima I, et al. Negative participation of the left posterior fascicle in the reentry circuit of verapamilsensitive idiopathic left ventricular tachycardia. J Cardiovasc Electrophysiol. 2012 ; 23 : 556-9.
PubMed
19) Maeda S, et al. First case of left posterior fascicle in a bystander circuit of idiopathic left ventricular tachycardia. Can J Cardiol. 2014 ; 30 : 1460. e11-13.
 
20) Liu Q, et al. Mechanisms of posterior fascicular tachycardia : The relationship between high frequency potentials and the ventricular myocardium. Circ Arrhythm Electrophysiol. 2016 ; 9 : pii : e003754.
 
21) Komatsu Y, et al. Fascicular ventricular tachycardia originating from papillary muscles : Purkinje-network involvement in the reentrant circuit. Circ Arrhythm Electrophysiol. 2017 ; 10 : pii : e004549.
 
22) Rivera S, et al. Anatomical connections between the papillary muscles and the ventricular myocardium. Circ Arrhythm Electrophysiol. 2019 ; 12 : e007004.
PubMed
23) Haissaguerre M, et al. Ventricular arrhythmias and the His-Purkinje system. Nat Rev Cardiol. 2016 ; 13 : 155-66.
PubMed
24) Caceres J, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989 ; 79 : 256-70.
PubMed
25) Blanck Z, et al. Bundle branch reentry : a mechanism of ventricular tachycardia in the absence of myocardial or valvular dysfunction. J Am Coll Cardiol. 1993 ; 22 : 1718-22.
 
26) Nogami A, et al. Bundle branch reentry tachycardia. In : Zipes DP, Jalife J, Stevenson WG, editors. Cardiac Electrophysiology : From Cell to Bedside (7th ed). Philadelphia : Elsevier ; 2018. pp. 799-813.
 
27) Chen H, et al. Electrophysiological characteristics of bundle branch reentry ventricular tachycardia in patients without structural heart disease. Circ Arrhythm Electrophysiol. 2018 ; 11 : e006049.
PubMed
28) Lopera G, et al. Identification and ablation of three types of ventricular tachycardia involving the His-Purkinje system in patients with heart disease. J Cardiovasc Electrophysiol. 2004 ; 15 : 52-8.
PubMed
29) Talib AK, et al. Non-reentrant fascicular tachycardia : Clinical and tlectrophysiological characteristics of a distinct type of idiopathic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2016 ; 9 : pii : e004177.
 
30) Leenhardt A, et al. Short-coupled variant of torsade de pointes. a new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994 ; 89 : 206-15.
PubMed
31) Haissaguerre M, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002 ; 106 : 962-7.
PubMed
32) Nogami A, et al. Mapping and ablation of idiopathic ventricular fibrillation from Purkinje system. Heart Rhythm. 2005 ; 2 : 646-9.
PubMed
33) Bansch D, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation. 2003 ; 108 : 3011-6.
PubMed
34) Komatsu Y, et al. Catheter ablation of refractory ventricular fibrillation storm after myocardial infarction : A multicenter study. Circulation. 2019 ; 139 : 2315-25.
PubMed
35) Haissaguerre M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003 ; 108 : 925-8.
PubMed
36) Bode K, et al. Ablation of polymorphic ventricular tachycardias in patients with structural heart disease. Pacing Clin Electrophysiol. 2008 ; 31 : 1585-91.
PubMed
37) Mlcochova H, et al. Catheter ablation of ventricular fibrillation storm in patients with infiltrative amyloidosis of the heart. J Cardiovasc Electrophysiol. 2006 ; 17 : 426-30.
 
38) Sinha AM, et al. Role of ventricular scar and Purkinje-like potentials during mapping and ablation of ventricular fibrillation in dilated cardiomyopathy. Pacing Clin Electrophysiol. 2009 ; 32 : 286-90.
PubMed
39) Cerrone M, et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2007 ; 101 : 1039-48.
 
40) Herron TJ, et al. Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2010 ; 7 : 1122-8.
PubMed
41) Kaneshiro T, et a. Effects of catheter ablation targeting the trigger beats in inherited catecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol. 2017 ; 3 : 1062-3.
PubMed
42) Gelberg HB. Purkinje fiber dysplasia (histiocytoid cardiomyopathy) with ventricular noncompaction in a savannah kitten. Vet Pathol. 2009 ; 46 : 693-7.
 
P.195 掲載の参考文献
1) 清水渉. 3) 遺伝性不整脈. 7-4 循環器疾患と遺伝子異常. 7. 循環器系の疾患 (分担). 矢崎義雄 (総編集), 内科学 (第11版). 東京. 朝倉書店 ; 2017. p. 423-7.
 
2) 清水渉. 4) 突然死. 7-6 不整脈. 7. 循環器系の疾患 (分担). 矢崎義雄 (総編集), 内科学 (第11版). 東京. 朝倉書店 ; 2017. p. 508-10.
 
3) 日本循環器学会, 他. 遺伝性不整脈の診療に関するガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_aonuma_h.pdf, (閲覧 : 2018-03-27)
 
4) Schwartz PJ, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009 ; 120 : 1761-7.
PubMed
5) Imboden M, et al. Female predominance and transmission distortion in the long-QT syndrome. N Engl J Med. 2006 ; 355 : 2744-51.
 
6) Shimizu W, et al. Association of genetic and clinical aspects of congenital long QT syndrome with life-threatening arrhythmias in Japanese patients. JAMA Cardiol. 2019 ; 4 : 246-54.
 
7) Mizusawa Y, et al. Genetic and clinical advances in congenital long QT syndrome. Circ J. 2014 ; 78 : 2827-33.
PubMed
8) Schwartz PJ, et al. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011 ; 124 : 2181-4.
 
9) Priori SG, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart rhythm. 2013 ; 10 : 1932-63.
PubMed
10) Shigemizu D, et al. Exome analyses of long QT syndrome reveal candidate pathogenic mutations in calmodulin-interacting genes. PLoS One. 2015 ; 10 : e0130329.
PubMed
11) Shimizu W, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol. 2003 ; 41 : 633-42.
PubMed
12) Shimizu W, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004 ; 1 : 276-83.
PubMed
13) Moss AJ, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007 ; 115 : 2481-9.
PubMed
14) Shimizu W, et al. Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol. 2009 ; 54 : 2052-62.
PubMed
15) Wilde AA, et al. Clinical aspects of type 3 long-QT syndrome : An International Multicenter Study. Circulation. 2016 ; 134 : 872-82.
PubMed
16) Brugada P, et al. Right bundle branch block, persistent ST segment elevation and sudden cardiac death : a distinct clinical and electrocardiographic syndrome : a multicenter report. J Am Coll Cardiol. 1992 ; 20 : 1391-6.
PubMed
17) Antzelevitch C, et al. J-Wave syndromes expert consensus conference report : emerging concepts and gaps in knowledge. J Arrhythm. 2016 ; 32 : 315-39.
PubMed
18) Yamagata K, et al. Genotype-phenotype correlation of SCN5A mutations for the clinical and electrocardiographic characteristics of probands with Brugada syndrome : a Japanese multicenter registry. Circulation. 2017 ; 135 : 2255-70.
PubMed
19) Kamakura S, et al ; Brugada Syndrome Investigators in Japan. Long-term prognosis of probands with Brugada-pattern ST elevation om V1-V3 leads. Circ Arrhythm Electrophysiol. 2009 ; 2 : 495-503.
 
20) Takagi M, et al ; Japan Idiopathic Ventricular Fibrillation Study (J-IVFS) Investigators. The prognostic value of early repolarization (J wave) and ST-segment morphology after J wave in Brugada syndrome : multicenter study in Japan. Heart Rhythm. 2013 ; 10 : 533-9.
 
21) Sacher F, et al. Syncope in Brugada syndrome patients : prevalence, characteristics, and outcome. Heart Rhythm. 2012 ; 9 : 1272-9.
PubMed
22) Ohgo T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007 ; 4 : 695-700.
PubMed
P.205 掲載の参考文献
1) Reynolds D, et al ; Micra transcatheter pacing study group. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016 ; 374 : 533-41.
 
2) Haines DE, et al. Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation. 2011 ; 123 : 2069-76.
PubMed
3) Boersma L, et al ; EFFORTLESS Investigator Group. Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry : The EFFORTLESS Study. J Am Coll Cardiol. 2017 ; 70 : 830-41.
PubMed
4) Daubert JP, et al ; MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II : frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008 ; 51 : 1357-65.
PubMed
5) Bardy GH, et al ; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 ; 352 : 225-37.
 
6) Tanno K, et al ; MADIT II. The Multicenter Automtic Defibrillator Implantation Trial. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J. 2005 ; 69 : 19-22.
 
7) Satake H, et al ; CHART-2 Investigators. Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure--a report from the CHART-2 Study. Circ J. 2015 ; 79 : 381-90.
PubMed
8) Kadish A, et al ; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004 ; 350 : 2151-8.
PubMed
9) Desai AS, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy : a meta-analysis of randomized controlled trials. JAMA. 2004 ; 292 : 2874-9.
PubMed
10) Shen L, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017 ; 377 : 1794-5.
PubMed
11) Cleland JG, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006 ; 27 : 1928-32.
PubMed
12) Kober L, et al ; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016 ; 375 : 1221-30.
PubMed
13) Moss AJ, et al ; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012 ; 367 : 2275-83.
PubMed
14) Auricchio A, et al ; PainFree SST Investigators. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms : PainFree SST trial primary results. Heart Rhythm. 2015 ; 12 : 926-36.
PubMed
15) Hindricks G, et al ; IN-TIME study group. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME) : a randomised controlled trial. Lancet. 2014 ; 384 : 583-90.
 
16) Barakat AF, et al. Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy : a meta-analysis of randomised controlled trials. BMJ Open. 2017 ; 7 : e016352.
PubMed
17) Golwala H, et al. Implantable cardioverter-defibrillator for nonischemic cardiomyopathy : An updated metaanalysis. Circulation. 2017 ; 135 : 201-3.
PubMed
18) 日本循環器学会, 他. 不整脈非薬物治療ガイドライン (2018年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2018_kurita_nogami.pdf, (閲覧 : 2018-05-08)
 
19) Moss AJ, et al ; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 ; 361 : 1329-38.
PubMed
20) Healey JS, et al ; RAFT Investigators. Cardiac resynchronization therapy in patients with permanent atrial fibrillation : results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012 ; 5 : 566-570.
PubMed
21) Ruschitzka F, et al ; EchoCRT Study Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013 ; 369 : 1395-405.
 
22) Ponikowski P, et al ; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 ; 37 : 2129-200.
 
23) De Pooter J, et al. Gender differences in electro-mechanical characteristics of left bundle branch block : potential implications for selection and response of cardiac resynchronization therapy. Int J Cardiol. 2018 ; 257 : 84-91.
PubMed
24) Varma N, et al. Interaction of left ventricular size and sex on outcome of cardiac resynchronization therapy among patients with a narrow QRS duration in the EchoCRT Trial. J Am Heart Assoc. 2018 ; 7 : e009592.
 
25) Hohnloser SH, et al ; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004 ; 351 : 2481-8.
PubMed
26) Olgin JE, et al ; VEST Investigators. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018 ; 379 : 1205-15.
PubMed
P.218 掲載の参考文献
1) Maron BJ, et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986 ; 8 : 545-57.
PubMed
2) Basso C, et al. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol. 2000 ; 35 : 1493-501.
PubMed
3) Shirani J, et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000 ; 35 : 36-44.
PubMed
4) Maron BJ, et al. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation. 1979 ; 59 : 689-706.
PubMed
5) Schumacher B, et al. Electrophysiological characteristics of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy and moderate to severe symptoms. Circulation. 2005 ; 112 : 2096-101.
PubMed
6) Choudhury L, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002 ; 40 : 2156-64.
PubMed
7) Puggia I, et al. Natural history of dilated cardiomyopathy in children. J Am Heart Assoc. 2016 ; 5 : pii : e003450.
 
8) Ichida F, et al. Clinical features of isolated noncompaction of the ventricular myocardium : long-term clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol. 1999 ; 34 : 233-40.
PubMed
9) Chin TK, et al. Isolated noncompaction of left ventricular myocardium : a study of eight cases. Circulation. 1990 ; 82 : 507-13.
PubMed
10) Oechslin EN, et al. Long-term follow-up of 34 adults with isolated left ventricular noncompaction : a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 2000 ; 36 : 493-500.
PubMed
11) Stollberger C, et al. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol. 2002 ; 90 : 899-902.
PubMed
12) Nakashima K, et al. A left ventricular non-compaction in a patient with long QT syndrome caused by a KCNQ1 mutation : a case report. Heart Vessels. 2013 ; 28 : 126-9.
 
13) Corrado D, et al. Arrhythmogenic right ventricular cardiomyopathy : diagnosis, prognosis, and treatment. Heart. 2000 ; 83 : 588-95.
PubMed
14) Lieberman EB, et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol. 1991 ; 18 : 1617-26.
PubMed
15) Engelfriet P, et al. The spectrum of adult congenital heart disease in Europe : morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J. 2005 ; 26 : 2325-33.
 
16) Oechslin EN, et al. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000 ; 86 : 1111-6.
PubMed
17) Diller GP, et al. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll Cardiol. 2006 ; 48 : 1250-6.
PubMed
18) Friedman RA, et al. NASPE expert consensus conference : radiofrequency catheter ablation in children with and without congenital heart disease. Report of the writing committee. North American Society of Pacing and Electrophysiology. Pacing Clin Electrophysiol. 2002 ; 25 : 1000-17.
PubMed
19) Chinen S, et al. Life-threatening atrial tachycardia after the Senning operation in a patient with transposition of the great arteries. Heart Vessels. 2012 ; 27 : 424-7.
 
20) Hebe J, et al. Radiofrequency catheter ablation of tachycardia in patients with congenital heart disease. Pediatr Cardiol. 2000 ; 21 : 557-75.
PubMed
21) Diller GP, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of fallot. Circulation. 2012 ; 125 : 2440-6.
PubMed
22) Palmieri V, et al. Anomalous origin of coronary arteries from the "wrong" sinus in athletes : diagnosis and management strategies. Int J Cardiol. 2018 ; 252 : 13-20.
PubMed
23) Roberts WC. Major anomalies of coronary arterial origin seen in adulthood. Am Heart J. 1986 ; 111 : 941-63.
PubMed
24) Maron BJ, et al. Sudden deaths in young competitive athletes : analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009 ; 119 : 1085-92.
PubMed
25) Patel S. Normal and anomalous anatomy of the coronary arteries. Semin Roentgenol. 2008 ; 43 : 100-12.
PubMed
26) Corrado D, et al. Non-atherosclerotic coronary artery disease and sudden death in the young. Br Heart J. 1992 ; 68 : 601-7.
 
27) 長田洋資, 他. 冠動脈起始異常により失神・心停止に至った2症例. 心電図. 2019 ; 39 (supple 2) : S-2-13-9.
 
28) Haissaguerre M, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008 ; 358 : 2016-23.
PubMed
29) McCorquodale A, et al. High prevalence of early repolarization in the paediatric relatives of sudden arrhythmic death syndrome victims and in normal controls. Europace. 2017 ; 19 : 1385-91.
 
30) Watanabe H, et al. Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricular fibrillation associated with early repolarization. Circ Arrhythm Electrophysiol. 2011 ; 4 : 874-81.
PubMed
31) Guo Q, et al. A novel mutation in the SCN5A gene contributes to arrhythmogenic characteristics of early repolarization syndrome. Int J Mol Med. 2016 ; 37 : 727-33.
PubMed
32) Burashnikov E, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm. 2010 ; 7 : 1872-82.
PubMed
33) Perrin MJ, et al. Evaluation of genes encoding for the transient outward current (Ito) identifies the KCND2 gene as a cause of J-wave syndrome associated with sudden cardiac death. Circ Cardiovasc Genet. 2014 ; 7 : 782-9.
PubMed
34) Leenhardt A, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995 ; 91 : 1512-9.
PubMed
35) Sumitomo N, et al. Catecholaminergic polymorphic ventricular tachycardia in children and young adults : electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003 ; 89 : 66-70.
 
36) Laitinen PJ, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001 ; 103 : 485-90.
PubMed
37) Priori SG, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001 ; 103 : 196-200.
PubMed
38) Lahat H, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia : clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation. 2001 ; 103 : 2822-7.
 
39) Devalla HD, et al. TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT. EMBO Mol Med. 2016 ; 8 : 1390-408.
PubMed
40) Nyegaard M, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet. 2012 ; 91 : 703-12.
PubMed
41) Jimenez-Jaimez J, et al. Calmodulin 2 mutation N98S is associated with unexplained cardiac arrest in infants due to low clinical penetrance electrical disorders. PLoS One. 2016 ; 11 : e0153851.
PubMed
42) Gomez-Hurtado N, et al. Novel CPVT-associated calmodulin mutation in CALM3 (CALM3-A103V) activates arrhythmogenic Ca waves and sparks. Circ Arrhythm Electrophysiol. 2016 ; 9 : pii : e004161.
 
43) Roux-Buisson N, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet. 2012 ; 21 : 2759-67.
PubMed
44) Leren IS, et. al. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selecitve in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016 ; 13 : 433-40.
 
45) Zhou Q, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med. 2011 ; 17 : 1003-9.
PubMed
46) Watanabe H, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009 ; 15 : 380-3.
PubMed
47) van der Werf C, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011 ; 57 : 2244-54.
PubMed
48) Hwang HS, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011 ; 4 : 128-35.
 
49) Kaneshiro T, et al. Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation. Circ Arrhythm Electrophysiol. 2012 ; 5 : e14-7.
PubMed
50) Schwartz PJ, et al. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011 ; 124 : 2181-4.
 
51) Dorostkar PC, et al. Long-term follow-up of patients with long-QT syndrome treated with β-blockers and continuous pacing. Circulation. 1999 ; 100 : 2431-6.
 
52) Odero A, et al. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias : the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm. 2010 ; 7 : 1161-5.
PubMed
53) Hwang SW, et al. Left thoracoscopic sympathectomy for refractory long QT syndrome in children. J Neurosurg Pediatr. 2011 ; 8 : 455-9.
 
54) Schwartz PJ, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004 ; 109 : 1826-33.
 
55) Antzelevitch C, et al. J-wave syndromes : Brugada and early repolarization syndromes. Heart Rhythm. 2015 ; 12 : 1852-66.
PubMed
56) Priori SG, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 ; 10 : 1932-63.
PubMed
P.229 掲載の参考文献
1) Mirowski M, et al. Termination of malignant ventricular arrhythmias with implanted automatic defibrillator in human beings. N Engl J Med. 1980 ; 303 : 322-4.
PubMed
2) Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 3 : adult basic life support. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000 ; 102 (8 Suppl.) : I22-59.
 
3) Valenzuela TD, et al. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med. 2000 ; 343 : 1206-9.
PubMed
4) Page RL, et al. Use of automated external defibrillators by a U. S. airline. N Engl J Med. 2000 ; 343 : 1210-6.
 
5) Mitamura H. Public access defibrillation : advances from Japan. Nat Clin Pract Cardiovasc Med. 2008 ; 5 : 690-2.
PubMed
6) 総務省消防庁. 平成30年版救急救助の現況. 2019. https://www.fdma.go.jp/publication/rescue/items/kkkg_h30_01_kyukyu.pdf, (閲覧 : 2019-05-15)
 
7) 日本循環器学会AED検討委員会, 日本心臓財団. AEDの具体的設置・配置基準に関する提言. 心臓. 2012 ; 44 : 392-402.
Medical*Online
8) Zijlstra JA, et al. Local lay rescuers with AEDs, alerted by text messages, contribute to early defibrillation in a Dutch out-of-hospital cardiac arrest dispatch system. Resuscitation. 2014 ; 85 : 1444-9.
 
9) Pijls RWM, et al. A text message alert system for trained volunteers improves out-of-hospital cardiac arrest survival. Resuscitation. 2016 ; 105 : 182-7.
PubMed
10) Murakami Y, et al. Outcomes of out-of-hospital cardiac arrest by public location in the public-access defibrillation era. J Am Heart Assoc. 2014 ; 3 : e000533.
PubMed
11) Mitani Y, et al. Public access defibrillation improved the outcome after out-of-hospital cardiac arrest in school-age children : a nationwide, population-based, Utstein registry study in Japan. Europace. 2013 ; 15 : 1259-66.
PubMed
12) Mitani Y, et al. Circumstances and outcomes of out-of-hospital cardiac arrest in elementary and middle school students in the era of public-access defibrillation. Circ J. 2014 ; 78 : 701-7.
PubMed
13) Kiyohara K, et al ; SPIRITS Investigators. Epidemiology of pediatric out-of-hospital cardiac arrest at school-an investigation of a nationwide registry in Japan. Circ J. 2018 ; 82 : 1026-32.
PubMed
14) Mitamura H, et al. Aiming for zero deaths : Prevention of sudden cardiac death in schools--Statement from the AED Committee of the Japanese Circulation Society. Circ J. 2015 ; 79 : 1398-401.
PubMed
15) Kiyohara K, et al. Exercise-related out-of-hospital cardiac arrest among the general population in the era of public-access defibnrillation : a population-based observation in Japan. J Am Heart Assoc. 2017 ; 6 : pii : e005786.
 
16) 日本循環器学会, 日本AED財団. 提言「スポーツ現場における心臓突然死をゼロに」. 2018. http://www.j-circ.or.jp/topics/aed_teigen.htm, (閲覧 : 2019-03-19)
 
17) Kinoshi T, et al. Mobile automated external defibrillator response system during road races. N Engl J Med. 2018 ; 379 : 488-9.
PubMed
18) Bardy GH, et al ; HAT Investigators. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med. 2008 ; 358 : 1793-804.
PubMed
19) Iwami T, et al. Dissemination of chest compression-only cardiopulmonary resuscitation and survival after out-of-hospital cardiac arrest. Circulation. 2015 ; 132 : 415-22.
PubMed
P.236 掲載の参考文献
1) 日本薬学会. 薬学用語解説 アドヒアランス. 2007. https://www.pharm.or.jp/dictionary/wiki.cgi?%e3%82%a2%e3%83%89%e3%83%92%e3%82%a2%e3%83%a9%e3%83%b3%e3%82%b9, (閲覧 : 2019-3-19)
 
2) Kolandaivelu K, et al. Non-adherence to cardiovascular medications. Eur Heart J. 2014 ; 35 : 3267-76.
PubMed
3) Banerjee A, et al. Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease : a systematic review. Open Heart. 2016 ; 3 : e000438.
PubMed
4) Bansilal S, et al. Assessing the impact of medication adherence on long term cardiovascular outcomes. J Am Coll Cardiol. 2016 ; 68 : 789-801.
PubMed
5) Naderi SH, et al. Adherence to drugs that prevent cardiovascular disease : meta-analysis on 376,162 patients. Am J Med. 2012 ; 125 : 882-7. e. 1.
 
6) Suzuki T, et al. Self-reported non-adherence to medication in Japanese patients with cardiovascular diseases. Am J Cardiovasc Drugs. 2018 ; 18 : 311-6.
PubMed
7) Yao X, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016 ; 5 : pii : e003074.
 
8) Patel MR, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation : analysis from the ROCKET AF tria (l Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013 ; 61 : 651-8.
 
9) Shore S, et al. Adherence to dabigatran therapy and longitudinal patient outcomes : insights from the veterans health administration. Am Heart J. 2014 ; 167 : 810-7.
PubMed
10) Obamiro KO, et al. A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation. Am J Cardiovasc Drugs. 2016 ; 16 : 349-63.
PubMed
11) Kimmel SE, et al. The influence of patient adherence on anticoagulation control with warfarin : results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007 ; 167 : 229-35.
PubMed
12) Gorst-Rasmussen A, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis : a nationwide cohort study. J Thromb Haemost. 2015 ; 13 : 495-504.
PubMed
13) McHorney CA, et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin. 2015 ; 31 : 2167-73.
PubMed
14) Crivera C, et al. Pharmacy quality alliance measure : adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin. 2015 ; 31 : 1889-95.
PubMed
15) Tsai K, et al. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care. 2013 ; 19 : e325-32.
 
16) Cutler TW, et al. A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manag Care Pharm. 2014 ; 20 : 1028-34.
 
17) Beyer-Westendorf J, et al. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016 ; 18 : 1150-7.
PubMed
18) Zhou M, et al. Adherence to a novel oral anticoagulant among patients with atrial fibrillation. J Manag Care Spec Pharm. 2015 ; 21 : 1054-62.
PubMed
19) Castellucci LA, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res. 2015 ; 136 : 727-31.
PubMed
20) Di Minno A, et al. Ensuring medication adherence with direct oral anticoagulant drugs : lessons from adherence with vitamin K antagonists (VKAs). Thromb Res. 2014 ; 133 : 699-704
 
21) Kneeland PP, et al. Current issues in patient adherence and persistence : focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence. 2010 ; 4 : 51-60.
PubMed
22) Suzuki T, et al. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. J Cardiol. 2017 ; 70 : 238-43.
PubMed
23) Fang MC, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 ; 3 : 624-31.
PubMed
24) Zalesak M, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013 ; 6 : 567-74.
PubMed
25) Shiga T, et al. Persistence of non-vitamin K antagonist oral anticoagulants use in Japanese patients with atrial fibrillation : a single-center observational study. J Arrhythm. 2015 ; 31 : 339-44.
PubMed
26) Beyer-Westendorf J, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015 ; 113 : 1247-57.
PubMed
27) Beyer-Westendorf J, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015 ; 17 : 530-8.
PubMed
28) Martinez C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost. 2016 ; 115 : 31-9.
PubMed
29) O'Brien EC, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 ; 168 : 487-94.
PubMed
30) Shore S, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015 ; 313 : 1443-50.
PubMed
31) Miller WR, Rollnick S. Motivational Interviewing : Helping people Change. 3rd ed. New York : Guilford Press ; 2012.
 

書評

最近チェックした商品履歴

Loading...